SCHEMBL30428018

SCHEMBL30428018

COCCOc1nc2[nH]ccc2cc1Oc1ccccc1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NR1I2 O75469 1/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ OPRK1 P41145 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ NUDT1 P36639 1/20 0.41
▸ HTT P42858 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CTNNB1 P35222 1/20 0.39
▸ AURKA O14965 2/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30428561 0.88 CTNNB1 (0.43) MAPTLMNAMEN1NR1I2CHRM2
SCHEMBL30428638 0.81 CTNNB1 (0.44) MAPTLMNAMEN1NR1I2CHRM2
SCHEMBL30429120 0.81 KDM4E (0.45) KDM4EAURKAJAK2JAK1RPS6KB1
SCHEMBL30428798 0.77 TTK (0.38) LMNANUDT1CTNNB1NPC1RAB9A
SCHEMBL1701635 0.74 CTNNB1 (0.51) NUDT1CTNNB1AURKBROCK2CCNT1
SCHEMBL23835432 0.73 LMNA (0.67) MAPTLMNAMEN1NR1I2CHRM2
SCHEMBL28730343 0.70 LMNA (0.64) MAPTLMNAMEN1NR1I2CHRM2
SCHEMBL25613045 0.68 ULK1 (0.39) LMNAHTTBRD4GRM4CDK8
SCHEMBL7693879 0.67 CTNNB1 (0.77) MAPTLMNAMEN1NR1I2CHRM2
SCHEMBL5249883 0.67 LMNA (0.74) MAPTLMNAMEN1NR1I2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 MAPT 2208/4885LMNA 1102/4885MEN1 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback